Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)

Abstract Background The combination of sofosbuvir and daclatasvir has shown preliminary efficacy for hospitalized patients with COVID-19 in four open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir/daclatasvir to standard care improved clinical...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2022-02, Vol.77 (3), p.758-766
Main Authors: Mobarak, Sara, Salasi, Mehdi, Hormati, Ahmad, Khodadadi, Javad, Ziaee, Masood, Abedi, Farshid, Ebrahimzadeh, Azadeh, Azarkar, Zohreh, Mansour-Ghanaei, Fariborz, Joukar, Farahnaz, Yeganeh, Sara, Yaghubi Kalurazi, Tofigh, Naghipour, Mohammadreza, Mehrabi, Zeinab, Bahadori, Amir Reza, Yaghoubi, Shoeleh, Moslemi, Rohollah, Abbaspour Kasgari, Hamideh, Fakheri, Hafez, Moghimi, Minoo, Shabani, Amir Mohammad, Nekoukar, Zahra, Babamahmoodi, Farhang, Davoudi Badabi, Ali Reza, Davoodi, Lotfollah, Hassaniazad, Mehdi, Barahimi, Elham, Tousi, Abdolali, Sadeghi, Anahita, Hosamirudsari, Hadiseh, Ali Asgari, Ali, Abdollahi, Mohammad, Anushiravani, Amir, Shabani, Minoosh, Shokouhi, Shervin, Khajavirad, Nasim, Salehi, Mohammadreza, Dehghan Manshadi, Seyed Ali, Mousavi, Hashem, Zolfaghari, Farnaz, Azimi, Elmira, Zeinali, Aida, Akbarpour, Elham, Merat, Dorsa, Eslami, Gholamali, Mousaviasl, Sajedeh, Sayar, Sara, Radmanesh, Esmat, Ebrahimzadeh, Mona, Arizavi, Zahra, Jelvay, Saeed, Salmanzadeh, Shokrollah, Esmaeilian, Hani, Mobarak, Morteza, Karimi, Jalal, Poormontaseri, Zahra, Hasooni Bahrini, Nasrollah, Bonyadi, Atefeh, Dehghani, Fatemeh, Mirzaei, Hadi, Noori Jangi, Masoome, Pourmasoomi, Hossein, Rezaie Keikhaie, Lili, Afshari, Mahdi, Nateghi Baygi, Alireza, Nateghi Baygi, Helia, Levi, Jacob, McCann, Kaitlyn, Wentzel, Hannah, Simmons, Bryony, Hill, Andrew, Merat, Shahin
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - therapeutic use
Carbamates
COVID-19
Humans
Imidazoles
Original Research
Pyrrolidines
SARS-CoV-2
Sofosbuvir - therapeutic use
Treatment Outcome
Valine - analogs & derivatives
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The combination of sofosbuvir and daclatasvir has shown preliminary efficacy for hospitalized patients with COVID-19 in four open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir/daclatasvir to standard care improved clinical outcomes in hospitalized patients with COVID-19. Methods This was a placebo-controlled, double-blind, randomized clinical trial in adults hospitalized with COVID-19 at 19 hospitals in Iran. Patients were randomized to oral sofosbuvir/daclatasvir 400/60 mg once-daily or placebo in addition to standard of care. Patients were included if they had positive PCR or diagnostic chest CT, O2 saturation
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkab433